Dallas County Chapter

DALLAS COUNTY EMERGENCY NURSES ASSOCIATION

NOVEMBER CHAPTER MEETING

THURSDAY, NOVEMBER 12, 2026 | 7:00-9:00 PM

Connect. Learn. Give Back.

FEATURED EDUCATIONAL PROGRAM

Rabies Ready:

Why Timely, Complete Post-Exposure Prophylaxis (PEP) Saves Lives

Stephen Scholand, MD

Consultant in Infectious Diseases, University of Arizona
Associate Professor of Medicine, Frank Netter School of Medicine

HYPERMUNES EDUCATIONAL SERIES
Program Reference #2462

DINNER + EDUCATION SPONSORED BY

GRIFOLS

This educational program is developed and funded by Grifols.

TOYS FOR TOTS HOLIDAY TOY DRIVE

Help us spread some holiday cheer!

Bring a NEW, UNWRAPPED TOY to donate at the in-person meeting.

JOIN US IN PLANO OR ONLINE

IN PERSON

Baylor Scott & White Medical Center - Plano

4700 Alliance Blvd
Plano, TX 75093

Lower-Level Classrooms 2 & 3

VIRTUAL VIA ZOOM

Scan to join

Meeting ID
854 3885 4785

COMING EARLY? BOARD OF DIRECTORS MEETING: 6:00-6:50 PM

Optional and open to DCENA members.

BRING A COLLEAGUE. BRING A TOY.

COME LEARN + CONNECT WITH DCENA!

Dallas County Emergency Nurses Association | dcena.org | DallasCountyENA@gmail.com

NEW + UNWRAPPED TOYS REQUESTED FOR OUR TOYS FOR TOTS DRIVE

HYPERMUNES™ EDUCATIONAL SERIES

Rabies Ready: Why Timely, Complete Post-Exposure Prophylaxis (PEP) Saves Lives

You are invited...

To attend a Hypermunes Educational Series program developed by Grifols, regarding the rabies threat in the US and the role of post-exposure prophylaxis.

Program Information

When: Thursday, November 12, 2026, at 7:00 PM CST

Where: Baylor Scott & White: Plano 4700 Alliance Boulevard Plano, TX 75093, Plano, TX

Speaker: Stephen Scholand, MD

Consultant in Infectious Diseases, University of Arizona Associate Professor of Medicine, Frank Netter School of Medicine North Haven, CT

Host: Alissa Sneed / alissa.sneed@grifols.com /

Registration Information

Register online here.

Reference Program #:

2462

You may also complete the accompanying registration form.

Email to grifols@bcdme.com

Fax to 770-677-5524

Or scan the QR code

If you prefer to register by phone or if you have any questions regarding this program, please call 833-591-3651.

Speaker programs are conducted in accordance with the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals. Attendance at this educational event is limited to healthcare professionals (HCPs) with a legitimate interest in the product for an FDA-approved indication or related disease state. HCPs may be subject to ethics laws or rules limiting their ability to accept a meal and should be familiar with any restrictions. For example, Minnesota healthcare practitioners are limited to a $50 "gift" cap, including meals, per calendar year, and Vermont HCPs may not receive food or beverage associated with this event. Federal employees are prohibited by government regulations from receiving meals valued in excess of $20 on any occasion and more than $50 in a calendar year from any single contractor, except incident to a society or membership unrelated to their government employment. The information on this form is being collected to comply with federal and state reporting requirements. Grifols does not provide or subsidize alcohol during Grifols-sponsored speaker programs.

HyperRAB®
Rabies Immune Globulin (Human)
300 IU/mL

Please see Important Safety Information for HyperRAB on following page and refer to accompanying full Prescribing Information for complete prescribing details.

This program is developed and funded by Grifols.

Important Safety Information for HyperRAB® (rabies immune globulin [human])

Indication and Usage

HyperRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use

Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

For unvaccinated persons, the combination of HyperRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.

Beyond 7 days (after the first vaccine dose), HyperRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Important Safety Information

For infiltration and intramuscular use only.

Severe hypersensitivity reactions may occur with HyperRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HyperRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HyperRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HyperRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HyperRAB administration.

Please see full Prescribing Information for HyperRAB.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

HyperRAB®
Rabies Immune Globulin (Human)
300 IU/mL

GRIFOLS

June 2026 US-HB3-2600030

This program is developed and funded by Grifols.